Inhibition of potassium- and ischemia-evoked [3H] D-aspartate release from isolated bovine retina by cannabinoids

Current Eye Research

Volumn 31, Issue 7-8, 2006, Pages 645-653

  Opere, Catherine ^a,c   Zheng, Wei ^a   Zhao, Min ^a   Lee, Jin ^a   Kulkarni, Kaustubh ^b   Ohia, Sunny ^b  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c CREIGHTON UNIVERSITY   (United States)

Author keywords

Aspartate; Excitoxicity neuroprotection and inhibition; Ischemia; Release

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; ARACHIDONYL 2' CHLOROETHYLAMIDE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; DEXTRO ASPARTIC ACID; METHANANDAMIDE; POTASSIUM CHLORIDE; POTASSIUM ION; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COW; DRUG EFFECT; DRUG POTENCY; ISCHEMIA; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RETINA;

ANIMALS; CANNABINOIDS; CATTLE; D-ASPARTIC ACID; DISEASE MODELS, ANIMAL; ISCHEMIA; POTASSIUM CHLORIDE; RETINA;

EID: 33746796735     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680600762747     Document Type: Article

References (70)

1. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Am Physiol Soc 2003;83:1017-1066.
2. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
3. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-64.
4. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87:1932-1936.
5. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain; A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 1992;48:655-668.
6. Westlake TM, Howlett AC, Bonner TI, et al. Cannabinoid receptor binding and messenger RNA expression in human brain: An in vivo receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience. 1994;63:637-652.
7. Glass M, Faull RLM, Dragunow M. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study on fetal neonatal and adult human brain. Neuroscience. 1997;77:299-318.
8. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54-61.
9. Ishac EJ, Jiang L, Lake KD, et al. Inhibition of exocytic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 1996;118:2023-2028.
10. Ameri A. Effects of cannabinoids on the brain. Prog Neurobiol. 1999;58:315-348.
11. Howlett AC, Barthe F, Bonner TI, et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161-202.
12. Jarvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther. 2002;95:203-220.
13. Straiker A, Stella N, Piomelli D, et al. Cannabinoid CB1 receptors and ligands in vertebrae localization and function of an endogenous signaling system. Proc Natl Acad Sci USA. 1999;96:14565-14570.
14. Yazulla S, Studholme KM, McIntosh HH, Fan SH. Cannabinoid receptors on goldfish retinal bipolar cells: electron-microscope immunocytochemistry and whole cell recordings. Vis Neurosci. 2000;17:391-401.
15. Straiker A, Maguire G, Mackie K, Lindsey J. Localization of the cannabinoid CB1 receptors in human anterior eye and retina. Invest Ophthalmol Vis Sci. 1999;20:2442-2488.
16. Lu Q, Straiker A, Lu G, Maguire G. Expression of CB2 receptor mRNA in adult rat retina. Vis Neurosci. 2000;17:91-95.
17. Yazulla S, Studholme KM, McIntosh HH, Deutsch DG. Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina. J Comp Neurol. 1999;415:80-90.
18. Sharif NA. Multiple synaptic receptors for neuroactive amino acid transmitters - new vistas. Int Rev Neurobiol. 1985;26:85-150.
19. Massey SC. Cell types using glutamate as a neurotransmitter in the vertebrate retina. Prog Retinal Res. 1990:399-425.
20. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999;43(6):S102-S128.
21. Marc RE. The role of glycine in the mammalian retina. Prog Retinal Res. 19889:67-107.
22. Benveniste H, Drejer J, Schousboe A, Diemer NM. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem. 1984;43:1369-1374.
23. Lu Y, Lu BF, Zhao FQ, et al. Accumulation of glutamate is regulated by calcium and protein kinase C in rat hippocampal slices exposed to ischemic states. Hippocampus. 1993;3:221-227.
24. Virgili M, Contestabile A, Barnabei O. Simultaneous blockade of non-NMDA ionotropic receptors and NMDA receptor-associated ionophore partially protects hippocampal slices from protein synthesis impairment due to simulated ischemia. Hippocampus. 1995;5(1):91-97.
25. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988;451:205-212.
26. Cox JA, Lysko PG, Henneberry RC. Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: Role of the voltage-dependent magnesium block. Brain Res. 1989;499:267-272.
27. Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23:1261-1276.
28. Shen M, Thayer SA. Δ-9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 1998;55(1):8-13.
29. Yoles E, Belkin M, Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J Neurotrauma. 1996;13(1):49-57.
30. Lopez-Colome A, Somohano F. Effect of selective kainate lesions on the release of glutamate and aspartate from check retina. J Neurosci Res. 1986;15:205-216.
31. (2+) independent release of [3H]D-aspartame from cultured chick retina cells. Neurochem Res. 1996;21:361-368.
32. Storm-Mathisen, J. Autoradiographic and microchemical localization of high affinity glutamate uptake. In: Roberts P, Storm-Mathisen J, Johnston C. Glutamate: Transmitter in the Central Nervous System. New York: John Wiley & Sons; 1981:89-115.
33. 3H]D-aspartate release: Role in excitotoxicity. Neurochem Res. 2000;25:853-860.
34. 3H]D- aspartate release from isolated bovine retina: Modulation by calcium-channel blockers and glutamatergic agonists and antagonists. Curr Eye Res. 2001;23(5):386-392.
35. 3H]D-aspartate release from isolated bovine and human retinae. J Ocular Pharmacol Ther. 2003;19:599-609.
36. Zablocka B, Domanska-Janik K. Enhancement of 3[H]D-aspartate release during ischemia like conditions in rat hippocampal slices: Source of excitatory amino acids. Acta Neurobiol Exp (Wars). 1996;56(1):63-70.
37. Rego AC, Santos MS, Oliveira CR. Oxidative stress, hypoxia, and ischemia-like conditions increase the release of endogenous amino acids by distinct mechanisms in cultured retinal cells. J Neurochem. 1996;66(6):2506- 2516.
38. Schlicker E, Timm J, Gothert M. Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:791-795.
39. Devanes WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949.
40. Sugiura T, Waku K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids. 2000;108(1-2):89-106.
41. Fride E, Foox A, Rosenbergc E, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: Evidence for a "CB3" receptor. Eur Pharmacol. 2003;461(1):27-34.
42. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400(6743):452-457.
43. Van der Stelt M, Di Marzo V. Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins Other Lipid Mediat. 2005;77(1-4):111-122.
44. Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686-691.
45. Hillard CJ, Manna S, Greenberg MJ, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999;289(3):1427-1433.
46. Abadji V, Lin S, Taha G, et al. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 1994;37:1889-1893.
47. Breivogel CS,Walker JM, Huang SM, et al. Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology. 2004;47(1):81-91.
48. Kofalvi A, Vizi ES, Ledent C, Sperlagh B. Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur J Neurosc. 2003;18(7):1973-1978.
49. Wang SJ. Cannabinoid CB1 receptor-mediated inhibition of glutamate release from rat hippocampal synaptosomes. Eur J Pharmacol. 2003;469(1-3):47-55.
50. Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006;1071(1):10-23. Epub 2006 Feb 9.
51. Small-Howard AL, Shimoda LM, Adra CN, Turner H. Antiinflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J. 2005;388(Pt 2):465-473.
52. Sterin-Borda L, Del Zar CF, Borda E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: Endogenous signal transduction pathways. Biochem Pharmacol 2005;69(12):1705-1713.
53. Huffman JW. CB2 receptor ligands. Mini Rev Med Chem. 2005;5(7):641-649.
54. Zhong L, Geng L, Njie Y, et al. CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 2005;46(6):1988-1992.
55. Bonz A, Kaser M, Kullmer S, et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol. 2003;41(4):657-664.
56. Mukherji S, Adams M, Whiteaker K, et al. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur J Pharmacol. 2004;505(1-3):1-9.
57. Lan R, Gatley J, Lu Q, et al. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: A potential human SPECT ligand. AAPS Pharm Sci. 1999;1(2):E4.
58. Kreitzer AC, Carter AG, Regehr WG. Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. Neuron. 2002;34(5):787-796.
59. Trettel J, Levine ES. Cannabinoids depress inhibitory synaptic inputs received by layer 2/3 pyramidal neurons of the neocortex. J Neurophysiol. 2002;88(1):534-539.
60. Kreitzer AC, Regehr WG. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci. 2001;21(20):RC174.
61. Wagner JA, Abesser M, Karcher J, et al. Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. J Cardiovasc Pharmacol. 2005;46(3):348-355.
62. Ford WR, Honan SA, White R, Hiley CR. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol. 2002;135(5):1191-1198.
63. Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 2001;106(1):1-4.
64. Shen M, Piser T, Seybold V, Thayer, S. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci. 1996;16:4322-4334.
65. Levenes C, Daniel H, Soubrie P, Crepel F. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol. 1998;510(Pt 3):867-879.
66. Werner NA, Koch JE. Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res. 2003;967(1-2):290-292.
67. Sinor AD, Irvin SM, Greenberg DA. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett. 2000;278:157-160.
68. Dreyer EB, Surakowski D, Schumer RA, et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114(3):299-305.
69. Carter-Dawson L, Crawford ML, Harwerth RS, et al. Vitreal glutamate concentration in monkeys with experimental glaucoma. Invest Ophthalmol Vis Sci. 2002;43(8):2633-2637.
70. Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol. 2004;88(5):708-713.